Sign up Australia
Proactive Investors - Run By Investors For Investors

Volpara Health Technologies developing products and international sales networks

Volpara Health Technologies (ASX:VHT) chief executive and co-founder Dr. Ralph Highnam explains to Proactive Investors the research, development, and manufacturing company's clinically-validated imaging analytics and analysis software. Volpara specialises in products that improve clinical decision-making and the early detection of breast cancer, boasting both US Food and Drug Administration (FDA) and Conformité Européenne (CE) mark approval.

The company is driving growth by pushing international sales, particularly in the USA, and by developing new capabilities, including some AI, that will push up revenue per patient. A $20 million raise to fund expansion plans has recently been completed. Volpara has set an annual recurring revenue goal of $9 million for this year.

View full VHT profile View Profile

Volpara Health Technologies Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use